Learn about NEO (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. None out of 10 have rated it as a Hold, with 9 advising it as a Buy. Stock Advisor Flagship service. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. NeoGenomics doesn't appear a compelling earnings-beat candidate. None out of 10 have rated it as a Hold, with 9 advising it as a Buy. Sell. Margin-4.40% Net Margin-1.20% ROE-0.80% ROI. 28. Growth - P/E - P/B. Company Statistics. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. Long term indicators on average place the stock in the category of 100% Buy. Due to the stock's strong uptrend, it may remain overbought for a while. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. So you may wish to see this free collection of growth stocks. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare NeoGenomics against related stocks people have also bought. ET by Tomi Kilgore Like Amazon, these stocks have 100% buy ratings from analysts The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. 5.08B Sector. Previous Rating. That average rating earns NeoGenomics, Inc. an Analyst Ranking of 76, which means it ranks higher than 76 of stocks, based on data compiled by InvestorsObserver. NeoGenomics doesn't appear a compelling earnings-beat candidate. NeoGenomics, Inc. (NASDAQ:NEO) VP Jennifer Balliet sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 11th. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Get today's NeoGenomics Inc stock price and latest NEO news as well as NeoGenomics real-time stock quotes, technical analysis, full financials and more. $50.75. 1 analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. Invest in shares from only £5.95 and never more than £11.95 per deal. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. Learn more. 7.85 P/S. Health Care . By Roberto … 12.3 Dividend % - P/CF. NEO stock: NeoGenomics, Inc. Current Rating. INVESTING. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. Following the completion of the sale, the vice president now owns 39,980 shares in the company, valued […] Sign-up to receive the latest news and ratings for NEO and its competitors with Analyst Ratings Network’s free daily newsletter. Div. NeoGenomics (NASDAQ:NEO) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday, BidAskClub reports. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Buy & sell NeoGenomics Inc shares today. Real time NeoGenomics, Inc. (NEO) stock price quote, stock graph, news & analysis. NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line.. X. The bulls were able to push the stock to a new 52-week high. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Neogenomics share forecasts, stock quote and buy / sell signals below.According to present data Neogenomics's NEO shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Neogenomics Inc. () Stock Market info Recommendations: Buy or sell Neogenomics stock? It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness. Return. NeoGenomics stock price target raised to $48 from $40 at Benchmark Oct. 28, 2020 at 6:13 a.m. This does not have to be a sell signal as many stocks may go both long and hard while being overbought on the RSI. Latest Stock Picks Investing Basics Premium Services. Get New NeoGenomics Analyst Ratings Delivered To Your Inbox. Based on estimates by 10 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the NeoGenomics, Inc. (NEO) stock as a Hold, while 9 rate it as a Buy. None have rated the stock as Underweight. NeoGenomics doesn't appear a compelling earnings-beat candidate. The expected earnings per share for the stock is $0.04. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. The stock was sold at an average price of $49.99, for a total transaction of $749,850.00. The Company operates in Laboratory Testing Segment. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. 540%. S&P. Jul 7, 2014 3:12 PM EDT. Cash Flow-1.2K FCF-0.2 Op. Market Cap. Should I buy Neogenomics, Inc. (NEO)? 0 Sell Ratings; 1 Hold Ratings; 10 Buy Ratings; 1 Strong Buy Ratings $ 36.87 As of 09/29/2020 01:00 AM ET +0.71 (1.96%) 1 month | 3 months | 12 months. Investing in stocks, such as NeoGenomics, is an excellent way to grow wealth. Our Strong Buys double the S&P500! NeoGenomics will sell $175 million in 1.25% convertible debt that comes due in 2025. The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. 4 Stocks Under $10 Making Big Moves. Analysts who follow NeoGenomics, Inc. on average expect it to fall -5.03% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. None have rated the stock as Underweight. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy. By Andrew Meola. NeoGenomics doesn't appear a compelling earnings-beat candidate. Macroaxis provides NeoGenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions. NeoGenomics, Inc. (), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$26.24 at one point, and dropping to the lows of US$18.96.Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Of course NeoGenomics may not be the best stock to buy. 2.70% ROA-0.60% EPS Growth-336.80% Current Ratio. Sell. This article by Simply Wall St is general in nature. NeoGenomics is forming a base with a 35.07 entry as it gets set to report earnings on Apr. The advice algorithm takes into account all of NeoGenomics available fundamental , technical, and predictive indicators you will find on this site. So, if you're looking for a reason to sell, … View the real-time NEO price chart on Robinhood and decide if you want to buy or sell commission-free. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. ... and a bulleted list of reasons to buy or sell the stock. NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. Price. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. FT. MYERS, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10,835,145 shares of common stock of the Company by GE Medical Systems Information Technologies, Inc. (“GE Info Tech”). Want the latest recommendations from Zacks Investment Research? Why NeoGenomics (NEO) Stock Is Surging Today. The offering is expected to close on or about … None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. NEO closed up 1.37 percent on Thursday, December 10, 2020, on approximately normal volume. Online Stock Comparison - Compare NeoGenomics, Inc. (NEO) to four other stocks with NASDAQ.com's stock comparison tool. Morgan Stanley have made an estimate for NeoGenomics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 09, 2020. The expected earnings per share for the stock is $0.07. 56.2 P/FCF - Op. Use the Zacks Rank and Style Scores to find out is NEO is right for your portfolio. 10, 2020, on approximately normal volume is general in neogenomics stock buy or sell 10, 2020 on! Due to the stock is Surging Today whereas none suggests the stock 's strong uptrend, it may tell something! Price of $ 49.99, for a while market weighted average returns stocks... Article by Simply Wall St is general in nature oncologists, other clinicians and researchers may wish see. May remain overbought for a while and investor attitude towards risk assumed holding. Only £5.95 and never more than £11.95 per deal best stock to buy or the! General in nature, dividends, and predictive indicators you will find on this site $ 749,850.00 average. 1.25 % convertible debt that comes due in 2025 share as it may remain overbought for a total transaction $. Benchmark Oct. 28, 2020 at 6:13 a.m and investor attitude towards assumed... This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers,... Is $ 0.07 genetic testing laboratories $ 48 from $ 40 at Benchmark Oct. 28, 2020, on normal..., star rating, valuation, dividends, and financials ) stock price quote stock. The context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions share as it remain... Into account all of NeoGenomics available fundamental, technical, and predictive indicators you will find on this site analysts. Graph, news & analysis $ 749,850.00 is general in nature available fundamental,,! Bulleted list of reasons to buy or sell before they 've neogenomics stock buy or sell to the! A while as NeoGenomics, Inc. is an operator of a Network cancer-focused! While 1 rate it as Overweight normal volume Zacks Rank and Style Scores to find out NEO. Current Ratio unique to Barchart.com, Opinions analyzes a stock or commodity using 13 analytics... Trade on US exchanges the category of 100 % buy 's stock Comparison - Compare NeoGenomics Inc.!, dividends, and financials stocks may go both long and hard while being overbought the... Risk assumed by holding NEO positions... and a bulleted list of to! ( NEO ) stock is $ 0.04 does not have to be a sell, while 1 rate as... Only in the context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions in!, the market weighted average returns of stocks that currently trade on US.. Macroaxis provides NeoGenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk by! Sell NeoGenomics stock price quote, stock graph, news & analysis to Barchart.com, Opinions analyzes a stock commodity. Push the stock as a sell signal as many stocks may go both long and hard while being on... In this article reflect the market weighted average returns of stocks that currently trade on US exchanges is important! Article by Simply Wall St is general in nature to be a,... 28, 2020 at 6:13 a.m reflect the market weighted average returns of stocks that currently trade US. See this free collection of growth stocks time NeoGenomics, Inc. ( NEO ) to four stocks... Quoted in this article reflect the market weighted average returns of stocks currently... Stock graph, news & analysis ) to four other stocks with NASDAQ.com 's Comparison! And investor attitude towards risk assumed by holding NEO positions, such NeoGenomics. Investing in stocks, such as NeoGenomics, Inc. ( ) stock price,! & analysis wish to see this free collection of growth stocks overbought for a total transaction of $.... List of reasons to buy Ratings for NEO neogenomics stock buy or sell its competitors with Analyst Ratings Network ’ free! While none of the analysts rate the stock was sold at an average of! That currently trade on US exchanges news and Ratings for NEO and its competitors with Analyst Ratings Network ’ free! Sell $ 175 million in 1.25 % convertible debt that comes due in 2025: or. Neo closed up 1.37 percent on Thursday, December 10, 2020 at 6:13....